ALS2

Amyotrophic lateral sclerosis 2, commonly known as ALS2, is a genetic disorder that affects motor neurons in the brain and spinal cord. This progressive degeneration leads to muscle weakness, spasticity, and eventually paralysis. ALS2 is distinct from other forms of amyotrophic lateral sclerosis (ALS) due to its specific genetic cause and typically earlier age of onset.

The primary cause of ALS2 is mutations in the ALS2 gene, which encodes a protein called alsin. Alsin plays a crucial role in the development and function of motor neurons. When the gene is mutated, the alsin protein is either absent or non-functional, leading to the death of motor neurons. The inheritance pattern is typically autosomal recessive, meaning an individual must inherit two copies of the mutated gene, one from each parent, to develop the condition.

Symptoms of ALS2 usually begin in childhood or adolescence, though adult-onset cases have been reported. Early signs often include difficulties with motor skills, such as clumsiness, slurred speech, and swallowing problems. As the disease progresses, muscle weakness becomes more pronounced, affecting limbs and the trunk. Respiratory muscles can also be impacted, leading to breathing difficulties.

Diagnosis involves a combination of clinical examination, neurological assessments, and genetic testing to identify mutations in the ALS2 gene. Currently, there is no cure for ALS2. Treatment focuses on managing symptoms to improve quality of life, including physical therapy, occupational therapy, speech therapy, and respiratory support. Research is ongoing to understand the disease mechanisms better and develop effective therapeutic strategies.